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Obesity is considered to be a state of chronic inflammation that leads to metabolic derangements.
Actually the relationship between obesity and bone loss is highly controversial. Obesity could be a protective factor due to endogenous estrogen production, but recent findings emphasize the positive relationship between obesity and bone loss. Other factors released from increased adipose tissue mass, free fatty acid (FFA), adipokine, and inflammatory cytokines are also necessary for consideration to evaluate the contribution of obesity to bone metabolism. FFA could be a potent candidate to cause bone loss. Hyperlipidemia is shown to decrease bone formation (1) , and increase bone resorption (2) . Statin, a lipid-lowering drug, has been demonstrated to increase bone mineral density (BMD) not only by a meta-analysis of clinical studies (3) , but also by an experimental animal model (4) . Absence of TLR4 increased BMD as well as decreased body fat (5) . Epidemiological studies also suggest that BMD is significantly related to serum lipid profiles (6) . Verma et al have demonstrated that marrow fat in bone biopsy samples is increased in osteoporosis (7) , and osteoporosis also has been connected to increased marrow fat content and decreased un-saturation of fat by studies using in vivo proton magnetic resonance spectroscopy (8) .
Increased adipose tissue mass is associated with changes in the endocrine and metabolic function of adipose tissue. FFA is a major secretory product from adipocytes as a result of lipolysis of stored triglycerides. FFA level is elevated in obesity along with various adipocyte factors, which are responsible for low-grade inflammation associated with obesity-related metabolic syndrome (9, 10) . Saturated fatty acid (SFA) induces the expression of pro-inflammatory genes in macrophages (11) , and SFA plays an essential role as signaling molecules in the chronic inflammatory disease associated with obesity (12) , although the mechanism by which they influence the development of chronic diseases is not clearly understood.
Osteoclasts (OC), multinucleated giant cells that can resorb bone cells, differentiate from hematopoietic stem cells. OC precursors have properties in common with precursors of the monocyte and macrophage cell lineages, which could cross-talk with adipocytes to reinforce inflammatory conditions (13) . They have an important role in physiological bone remodeling as well as participate in the bone destruction associated with chronic inflammatory disease (14) .
In the present study we investigated whether obesity-induced FFA in bone marrow environment affects bone metabolism by acting on OC. We found that SFA such as lauric acid or palmitic acid increased OC survival. Using Toll-like receptor 4 (TLR4)-knockout (KO) mice and myeloid differentiation factor 88 (MyD88)-KO mice, we explored the role of TLR4 and MyD88 in the OC survival induced by SFA.
MATERIALS AND METHODS

Reagents
Recombinant mouse M-CSF, RANKL, and recombinant mouse MIP-1α were obtained from R & D Systems, Inc. (Minneapolis, MN). Antibodies against CD11b, F4/80, CD3, and CD45R were obtained from eBioscience (SanDiego, CA). Bovine serum albumin (BSA) (fatty acid-free and low endotoxin) was purchased from Sigma Chemical Co. (St. Louis, MN), and the sodium salts of lauric acid, palmitic acid, stearic acid, oleic acid, linoleic acid, and cis-5, 8, 11, 14, 17-eicosapentaenoic acid (EPA) were from Nu-Chek (Eslyan, MN). BSA and all fatty acids within used concentration ranges contained undetectable amounts (<0.03 EU/ml) of endotoxin by E-TOXATE kit (Sigma Chemical Co.). No significant increase of MIP-1α was found at 0.03 EU/ml of endotoxin by mature OC. All free fatty acids (FFA) were solubilized in ethanol as described (11) . They were mixed with fatty acid-free and low endotoxin BSA at a molar ratio of 10:1 in 0.25% fetal bovine serum. Fatty acid-albumin complex solution was freshly prepared prior to each experiment. The same volume of vehicle was added to the controls as was added with FFA.
Animals
Male C57BL/6J mice were rendered obese by ingesting a high-fat diet (obese) (45% calories from lard and soybean oil) (Research Diets Inc.) for 13 weeks starting at 9 weeks of age. Control mice (lean) were fed a control diet (10% calories from soybean oil). All mice were housed in the specific pathogen-free animal facility of the University of Ulsan, Immunomodulation Research Center (IRC), and were handled in accordance with the Institutional Animal Care and Use Committee of the IRC.
Standards were approved by that Committee. Serum levels of FFA were 0.664 and 1.309 mEq/L for lean (n = 12) and obese (n = 19) mice, respectively. To measure FFA in bone marrow, femora were removed and dissected free of adherent soft tissue. The bone ends were cut, and the marrow cavity was flushed out with α-MEM from one end of the bone, using a sterile 21-gauge needle. The FFA content of bone marrow was determined by colorimetric analysis of nonesterified fatty acids using a NEFA kit (Wako Chemicals, Japan). The average bone marrow volume of mice was determined to be ~57 ul/femur.
Osteoclast formation
Bone marrow cells (typically three per preparation) were isolated from 4-5-week-old C57BL/6J mice as described (15 
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Statistical Analysis
All values are expressed as means ± SEM. Student's t-test was used to evaluate differences between samples of interest and the corresponding controls. A P value of less than 0.05 was considered statistically significant.
RESULTS
Osteoclastogenesis is stimulated by SFA
To investigate whether obesity affects the bone marrow microenvironment, we determined the levels of FFA in the bone marrow of lean and obese mice. As shown in Fig. 1A , the level of FFA in the bone marrow of obese mice was significantly higher than in that of lean mice, suggesting that increased FFA could affect the bone metabolism. Consistent with biochemical analyses, histology has demonstrated an increase in bone adiposity in obese mice (Fig. 1B) . Adipocyte number was elevated in proximal tibia of obese mice, compared to lean mice. Since bone loss is more associated with content of saturated fat than with unsaturated fat (9), we focused on whether SFA play a role in osteoclastogenesis.
We determined the effect of SFA on cultures of BMM free of stromal cells and lymphocytes to investigate the direct action on OC. SFA was added to separate cultures during the indicated period after BMM was incubated with M-CSF and RANKL. Lauric acid (C12:0) significantly increased the number of TRAP-positive MNC formed by the BMM when added on 2-4D or 3-4D, and palmitic acid (C16:0) was less potent (Fig. 2A) . However, exposure to SFA at early stage did not affect OC formation significantly, suggesting that SFA affects mature OC, rather than early OC precursor.
Since the stimulatory effect of SFA was prominent in the later stage of osteoclastogenesis, we tested whether it affected OC survival. As M-CSF or RANKL is also an OC survival factor (17), we removed cytokines from cultures of differentiated OC by washing them on day 4. The cells were then incubated in the presence or absence of SFA for an additional 18 h. As shown in Fig. 2B , the number of mature OC was reduced dramatically in the absence of cytokines, while the reduction was restored in the presence of M-CSF and RANKL. Treatment with lauric acid or palmitic acid alone prevented some loss of mature OC with maximum effect at 50 uM, although its effect was less than that of M-CSF and RANKL. Next, we determined by annexin V staining whether the effect of SFA on survival was due to an anti-apoptotic action (Fig. 2C) . As a positive control we observed fewer annexin V-positive OC in the presence of M-CSF and RANKL than when cytokines were removed. Cells incubated with lauric acid or palmitic acid alone also contained fewer annexin V-positive cells, indicating that SFA protects mature OC from apoptosis.
Enhanced OC survival is mediated by a signal through TLR4 and MyD88
Since SFA-induced COX-2 expression in murine macrophage is mediated by a signaling pathway derived from TLR4 (11), and OC expresses TLR4 (18), we examined whether SFA stimulates the survival of OC via TLR4. We prepared mature OC from C3H/HeJ mice that are defective of TLR4, and compared its response to SFA with that of C3H/HeN (wild type). Lauric acid or palmitic acid alone significantly increased the survival of OC derived from C3H/HeN, but not in that from C3H/HeJ mice (Fig. 3A) . This indicates that TLR4-mediated signals are essential for the effect of SFA on OC survival.
Since signaling through TLR4 involves subsequent recruitment of the adaptor molecule MyD88 (19), we determined whether MyD88 was also required for SFA signaling, using MyD88-KO mice. As shown in Fig. 3B (Fig. 3C) . However, NF-κB activation upon SFA stimulation was not found in mature OC from MyD88-KO mice and C3H/HeJ (TLR4-KO) mice (Fig. 3D) .
MIP-1α generated by mature OC in response to SFA is responsible for the increased OC survival
To investigate the factors enhancing OC survival, we first measured the expression of MIP-1α. The induction of MIP-1α transcripts in mature OC was significantly up-regulated after 3 h of lauric acid addition, and palmitic acid also increased MIP-1α transcripts though to a lesser degree (Fig. 4A) . To determine the effect of a wide range of FFA using the most sensitive assay, we have determined the expression of MIP-1α transcript (Fig. 4B) . The effect of stearic acid (C18:0) was more intense than that of palmitic acid (C16:0), but oleic acid (C18:1), linoleic acid (C18:2), or EPA had no significant effect.
Next we examined the level of MIP-1α secreted by mature OC. As shown in Fig. 4C , mature OC produced a significantly higher level of MIP-1α after addition of lauric acid or palmitic acid than after addition of vehicle. The OC survival factors, M-CSF and RANKL, also increased expression of MIP-1α, suggesting a role of MIP-1α in the elevated OC survival. We also tested whether SFA affects the expression of receptor for MIP-1α. No increased expression of CCR1 or CCR5 in mature OC was observed in response to lauric acid (data not shown). Since SFA did not change the expression level of receptor for MIP-1α. on mature OC, we examined whether the enhanced OC survival due to SFA was the result of increased MIP-1α. Treatment with MIP-1α alone prevented the loss of mature OC. Addition of neutralizing Ab against MIP-1α to cultures of lauric acid-or palmitic acid-treated OC prevented the increase in OC survival, whereas control IgG had no significant effect (Fig. 4D) (23). Lower BMD and rapid bone loss is associated with the advanced aortic calcification, a surrogate marker for atherosclerosis, in postmenopausal women (24) , and a graded association is also found between atherosclerotic vascular calcification and vertebral bone loss (25) .
FFA also causes inflammation by activation of JNK and IKKβ in muscle and liver (9) as well as macrophages (12) . Macrophages not only play a critical role as an inflammatory mediator in metabolic syndromes (13) , but also participate in the bone loss associated with chronic inflammatory disease (14) .
Indeed we have shown that SFA stimulates osteoclastogenesis by acting on mature OC, suggesting that they could play a critical role to induce bone loss along with obesity.
Contrary to our results, inhibition or no significant effect of OC formation by SFA in murine macrophage cell line, RAW264.7 cells, has been reported (26, 27) . However, they did not distinguish effect of SFA at specific stage. We have presented evidence that SFA is most effective in inducing osteoclastogenesis at a late stage of OC formation, and do so by enhancing OC survival by inhibiting apoptosis of the mature OC via a signal though TLR4, MyD88, and NF-κB. To see whether SFA stimulated the survival of OC through TLR4, mature OC were prepared from TLR4-KO mice. SFA unsaturated fatty acids on a TLR agonist, LPS, abolishes its activities, and turns it into an antagonist (29) , suggesting that SFA is responsible for the effects of TLR agonists. The role of TLR in osteoclastogenesis is controversial, but the difference could be due to stage that OC was exposed to TLR agonists. TLR stimulation inhibits OC formation (30) , whereas it enhances OC survival (18) . Actually in vivo excessive bone resorption by OC in inflammatory bone diseases is related to bacterial infection, probably as a consequence of activation of TLR (31) .
Conserved cytoplasmic regions of TLR associate with MyD88, which is also an adaptor molecule for IL-1 and LPS (19) . We have also shown that SFA alone did not promote the survival of OC from
MyD88-KO mice, suggesting that MyD88 is required for signaling from SFA. In addition, the number of OC was somewhat lower in vehicle-treated cultures from MyD88-KO mice (Fig. 3B ) than in those from wild type mice (Fig. 2B ), indicating that OC survival could be enhanced by endogenous molecules signaling through MyD88. However, the absence of TLR4 did not change basal level of OC significantly (Fig. 3A) . It could be explained by the redundancy of TLR. TLR form a complex with MyD88, IRAK, and TRAF6 (28) . Signaling by the latter induces activation of NF-κB (20) , and increased OC survival is associated with activation of NF-κB (20) . Our data also demonstrate that SFA causes activation of NF-κB in mature OC. However, NF-κB activation upon SFA stimulation was absent in TLR4-deficient cells as well as MyD88-deficient ones, indicating that NF-κB activation by SFA is due to a signal through TLR4 and MyD88. We can not exclude the possibility of a delayed response of SFA, since we do not perform kinetics of NF-κB activation. NF-κB activation by LPS is delayed, but not absent in MyD88-deficient cells, suggesting that certain LPS-induced responses do not require MyD88 (32) .
We showed that exogenously added SFA affects osteoclastogenesis induced by RANKL by modulating the level of MIP-1α, although it was not demonstrated clearly whether MIP-1α is a downstream molecule of the above signaling pathway. Our data indicate that MIP-1α is a positive regulator of OC survival, and that the enhanced OC survival of SFA-treated OC may be, at least partly, due to the increased level of MIP-1α. We also determined the effect of a variety of FFA on inducing MIP-1α. SFA had effect, but it is hard to tell the relationship between the magnitude of effect and chain length due to a small sample size. On the contrary, no significant effect was found with unsaturated fatty In conclusion, we found that SFA promoted OC survival by preventing from apoptosis. The stimulation of OC survival in SFA-treated OC was caused by an increased level of MIP-1α and a signal via TLR4, MyD88, and NF-κB activation; thus signaling pathway from SFA has both physiological and pathophysiological implications. The induction of MIP-1α by SFA may be an important component of OC survival. MIP-1α is also expressed in primary cultures of preadipocytes, and up-regulated during adipocyte differentiation (37) , suggesting the occurrence of autocrine and paracrine signaling in OC. In 
